• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

    11/17/22 4:15:00 PM ET
    $EPIX
    $PBYI
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EPIX alert in real time by email

    Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately.

    "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and small molecules in solid tumors nicely supplements our team's expertise in the areas of focus for our business development activities:  her wealth of experience will be invaluable to us as we seek to develop and advance medicinal therapies to the next level in oncology as a part of the next chapter of Team Summit."

    Dr. Cesano is the Chief Medical Officer (CMO) at Essa Pharma Inc. (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. Previously, she was the CMO at NanoString Inc. and Cleave Biosciences. She has 25 years of experience in the biopharmaceutical industry focused in oncology, including extensive experience at Biogen, Amgen, and GSK. She was instrumental in the development and approval of two marketed drugs including Vectibix® (panitumumab), an anti-EGFR antibody for the treatment of certain colorectal cancers. Dr. Cesano currently serves on the board of Puma Biotechnology Inc. (NASDAQ:PBYI), a clinical stage oncology company focused on solid tumors. She graduated from the University of Turin with her PhD in tumor immunology and her MD. She is a Board Certified oncologist in Europe.

    "I am truly excited to join Team Summit as we seek to make a meaningful impact on the lives of cancer patients facing incredible hardships as they fight this terrible disease," stated Dr. Cesano. "I have spent much of my life aligned with the mission and goals of Summit:  prioritizing the patient to bring about new advancements in oncology with patient, physician, caregiver, and societal-friendly medicines. I am excited to get to work with this exceptional group of leaders to truly change the outlook for patients with therapies that improve both quality and duration of life."

    Summit Therapeutics' Mission Statement

    To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, and successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs. To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate.

    We accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position. Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.

    About Summit Therapeutics

    Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT'). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK and Cambridge, UK.

    For more information, please visit https://www.summittxinc.com and follow us on Twitter @summitplc.

    Contact Summit Investor Relations:

    Dave Gancarz

    Head of Stakeholder Relations & Corporate Strategy

    [email protected]

    General Inquiries: 

    [email protected]

    Summit Forward-looking Statements

    Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, the therapeutic potential of the Company's product candidates, the potential commercialization of the Company's product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company's operations and clinical trials, potential acquisitions and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of our evaluation of the underlying data in connection with the topline results of our Phase III Ri-CoDIFy study evaluating ridinilazole, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, and global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company's pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ridinilazole. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.



    Primary Logo

    Get the next $EPIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EPIX
    $PBYI
    $SMMT

    CompanyDatePrice TargetRatingAnalyst
    Summit Therapeutics Inc.
    $SMMT
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    Summit Therapeutics Inc.
    $SMMT
    3/21/2025Overweight
    Cantor Fitzgerald
    Summit Therapeutics Inc.
    $SMMT
    3/12/2025$30.00Outperform
    Evercore ISI
    Summit Therapeutics Inc.
    $SMMT
    2/28/2025$42.00Buy
    Goldman
    Summit Therapeutics Inc.
    $SMMT
    1/8/2025$35.00Buy
    Truist
    Summit Therapeutics Inc.
    $SMMT
    12/11/2024$30.00Overweight
    Wells Fargo
    Summit Therapeutics Inc.
    $SMMT
    12/6/2024$31.00Buy
    Jefferies
    ESSA Pharma Inc.
    $EPIX
    11/4/2024Buy → Hold
    Jefferies
    More analyst ratings

    $EPIX
    $PBYI
    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

      5/8/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 12,875 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, April 1, 2025 a

      5/6/25 5:15:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    $PBYI
    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Summit Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Summit Therapeutics from Neutral to Buy and set a new price target of $35.00 from $23.00 previously

      3/26/25 7:47:33 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Summit Therapeutics

      Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight

      3/21/25 8:11:46 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Summit Therapeutics with a new price target

      Evercore ISI initiated coverage of Summit Therapeutics with a rating of Outperform and set a new price target of $30.00

      3/12/25 7:33:36 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    $PBYI
    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:17:22 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by COO and CFO Soni Manmeet Singh

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:13:55 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:09:55 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    $PBYI
    $SMMT
    Financials

    Live finance-specific insights

    See more

    $EPIX
    $PBYI
    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Puma Biotechnology Reports First Quarter Financial Results

      Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2025 was $43.1 million, compared to product revenue, net of $40.3 million in the first quarter of 2024. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $3.0 million, or $0.06 per basic and diluted share, for the first quarter of 20

      5/8/25 4:05:00 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

      5/8/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

      Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic

      5/1/25 4:09:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 7:32:27 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 4:04:37 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 6:56:05 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    $PBYI
    $SMMT
    SEC Filings

    See more
    • Puma Biotechnology Inc filed SEC Form 8-K: Leadership Update

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/9/25 8:57:31 AM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Puma Biotechnology Inc

      10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/8/25 4:41:37 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)

      5/8/25 4:20:43 PM ET
      $PBYI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    $PBYI
    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:28:30 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dhingra Ankur bought $375,000 worth of shares (100,000 units at $3.75) (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:27:03 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      12/18/23 9:57:03 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPIX
    $PBYI
    $SMMT
    Leadership Updates

    Live Leadership Updates

    See more
    • Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

      Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

      3/17/25 4:24:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

      3/6/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

      Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member

      6/27/24 4:15:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care